Description

MabThera (Rituximab) 500 mg/50 ml Injection – Uses, Benefits & Details

MabThera (Rituximab) 500 mg/50 ml is a powerful monoclonal antibody injection used in the treatment of blood cancers and autoimmune disorders. It is specifically designed to target CD20 proteins on B lymphocytes, leading to the destruction of abnormal or overactive B cells. This mechanism helps in managing conditions such as Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis, Granulomatosis with Polyangiitis (GPA), and Microscopic Polyangiitis (MPA).

---

Key Features of MabThera (Rituximab) Injection

• Active Ingredient: Rituximab 500 mg/50 ml (10 mg/ml concentration)

• Mode of Action: Targets CD20 antigens on B cells, triggering cell death through apoptosis, antibody-dependent cellular cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC).

• Administration: Intravenous infusion under medical supervision (average infusion time: 2–4 hours).

• Therapeutic Effects: Rapid B-cell depletion, reduced inflammation, improved disease control, and prolonged remission.

---

Medical Uses of MabThera (Rituximab)

• Non-Hodgkin’s Lymphoma (NHL): Effective alone or with chemotherapy.

• Chronic Lymphocytic Leukemia (CLL): Administered in combination with chemotherapy for better outcomes.

• Rheumatoid Arthritis: Used when patients do not respond to standard treatments, often with methotrexate.

• GPA & MPA (Vasculitis): Combined with corticosteroids to manage severe autoimmune inflammation.

---

Benefits of MabThera

• Targeted Therapy: Specifically destroys CD20-positive B cells without harming stem cells or plasma cells.

• Prolongs Remission: Effective as induction and maintenance therapy.

• Clinically Proven: Shown to improve survival rates in NHL and CLL patients.

• Autoimmune Support: Reduces autoantibody production, helping control rheumatoid arthritis and vasculitis.

---

Dosage & Administration

• NHL: 375 mg/m² once weekly for 4 weeks (induction), followed by maintenance every 2 months.

• CLL: 375 mg/m² (Day 0 of Cycle 1), then 500 mg/m² from Cycle 2 onward.

• RA: Two 1000 mg infusions given two weeks apart; repeat as per clinical need.

• GPA & MPA: 375 mg/m² weekly for 4 weeks (induction), with maintenance therapy as required.

⚠️ Important: MabThera must be given in a hospital setting by trained healthcare professionals. Premedication with antihistamines or analgesics may be required to reduce infusion reactions.

---

Storage Instructions

• Store between 2°C to 8°C (36°F – 46°F).

• Do not freeze.

• Use before the expiry date mentioned on the packaging.

---

Possible Side Effects

Like all powerful medications, MabThera may cause side effects including infusion reactions, low immunity, or increased risk of infections. Patients should be closely monitored during and after treatment.

---

Why Choose MabThera (Rituximab)?

• Trusted Worldwide: Widely used in oncology and rheumatology.

• Targeted Therapy: Provides selective action with better outcomes.

• Versatile Applications: Suitable for both cancer and autoimmune disorders.